Please login to the form below

Not currently logged in

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics

Versartis has named Joshua Brumm as its first chief financial officer.

Brumm joins from Pharmacyclics where he was principal financial officer and executive VP of finance.

He already has life sciences financial experience, having previously served as chief financial officer for Zeltiq Aesthetics and director of finance at Proteolix.

In his new role at Versartis, Brumm will lead the company's financial operations as it prepares to for the commercialisation of its phase III prospect VRS-317, which is in development as a treatment for growth hormone deficiency.

The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."

18th December 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?